Gene silencing company NeuBase reverse-merging with Ohr

Ophthalmic company Ohr Pharmaceutical Inc. (NASDAQ:OHRP) will reverse-merge with gene silencing company NeuBase Therapeutics Inc. (New York, N.Y.). The resulting public company will retain NeuBase's name and develop the private NeuBase's peptide-nucleic acid antisense oligonucleotide (PATrOL) platform.

NeuBase shareholders are expected to own 80% of the merged company and Ohr shareholders 20%. NeuBase's executive team, including CEO Dietrich Stephan, will lead the combined company...